Articles related to Pharmacy (Managed Care)

Healthcare leaders speaking at AXS26 argued that artificial intelligence tools affecting patient care require stronger oversight, including independent validation, bias monitoring, and human review. The discussion highlighted both operational opportunities and safety concerns surrounding healthcare AI adoption.

The FDA classified a recall of thyroid tablets USP 30 mg as Class I after identification of a superpotent product lot. The recall affects 1,955 bottles and carries risk of serious adverse health consequences, making prompt inventory review and product removal necessary.

A novel liposomal drug-delivery system prolonged tetrodotoxin nerve blockade to two to three weeks in rats, substantially exceeding currently available formulations. The findings highlight a potential strategy for sustained local anesthetic delivery, although clinical relevance remains unproven pending human validation.

New consensus guidance favors once-daily oral iron and simplified IV administration, including fewer test doses, premedications, and infusion visits. Several recommendations depart from established protocols and require formulation-specific clinical judgment.

HRSA’s revised 340B rebate pilot could require covered entities to purchase selected high-cost drugs at full price and recover discounts through manufacturer rebates beginning in 2027, prompting hospitals to evaluate data infrastructure, vendor readiness, and reimbursement workflows while legal and congressional challenges continue.

A multisociety consensus paper outlines hospital-level strategies to improve sepsis outcomes, emphasizing diagnostic stewardship, antimicrobial optimization, surveillance, infection prevention, and multidisciplinary infrastructure while prioritizing interventions judged most feasible and impactful for broad implementation.